The cost of a treatment course of serplulimab (a PD‑1 inhibitor) is affected by multiple factors, including the patient’s body weight, treatment regimen, dosing cycle, and regional price differences. The domestic price per vial (300 mg specification) is approximately USD 435–724, and the total cost for a full treatment course (usually 6–8 doses) may range from USD 7,234 to 21,702, depending on the clinical protocol and medical insurance policies.
Key Factors Affecting Cost
1. Patient Body Weight and Dosage
Serplulimab dosage is calculated based on body weight (typically 3 mg/kg); higher body weight means a larger single dose. For example, a 60 kg patient requires 2 vials (300 mg/vial) per dose, costing about RMB 6,000–10,000; an 80 kg patient may need 3 vials, resulting in higher costs.
2. Treatment Cycle and Number of Doses
For most indications (e.g., non‑small cell lung cancer), administration is required every 3 weeks until disease progression or unacceptable toxicity occurs.
Taking a 6‑month period (about 8 doses) as an example, the total cost may reach USD 11,575–28,936, subject to adjustment based on the patient’s condition.
3. Regional and Hospital Pricing Differences
Pricing varies by medical insurance policies and hospital tender prices in different regions. Some provinces reduce out‑of‑pocket expenses through national medical insurance negotiations or local supplementary insurance. It is recommended to consult the pharmacy of the treating hospital or the local medical insurance authority.
4. Indications and Combination Therapy
Serplulimab may be used in combination with chemotherapy or other medications (e.g., bevacizumab), and combination regimens will increase the overall treatment cost.
Cost Optimization Recommendations
Medical Insurance Reimbursement
Some indications (such as MSI‑H/dMMR solid tumors) have been included in the National Medical Insurance Catalog, reducing out‑of‑pocket expenses by 30%–70% after reimbursement.
Patient Assistance Programs
Some pharmaceutical companies or charitable organizations offer medication assistance, and eligible patients can apply for partial fee reductions.
Clinical Trials
Eligible patients can participate in clinical trials to receive free drug treatment.
Precautions
Use as Prescribed
Serplulimab is a prescription drug. It must be used strictly in accordance with the individualized regimen formulated by a doctor; do not adjust the dosage or discontinue use without medical advice.
Regular Follow‑ups
Efficacy and adverse reactions (e.g., immune‑related pneumonitis, hepatitis) should be monitored during treatment to avoid additional medical expenses caused by side effects.
Medical Guidance
Treatment is recommended at a specialized cancer hospital or a tertiary Grade A hospital. Doctors will optimize the regimen based on disease progression and the patient’s financial situation.
The actual cost shall prevail at the treating hospital. It is recommended to communicate with the attending physician and medical insurance department in advance to clarify cost details and reimbursement procedures.
